C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors. 2008

Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
Department of Chemistry, University of Cape Town, Rondebosch 7701, Cape Town, South Africa. Roger.Hunter@uct.ac.za

Several novel thiourea derivatives of the NNRTI HI-236 substituted at the C-2 oxygen of the phenyl ring have been synthesized and evaluated for their inhibitory activity against HIV-1 (IIIB) replication in MT-2 cell cultures. The compounds were synthesized in order to fine-tune the activity of HI-236 as well as to gain insight into spatial characteristics in the pocket pertaining to the positional choice of tether in the design of [NRTI]-tether-[HI-236] bifunctional inhibitors. Two of the thiourea derivatives bearing a butynyl (6c) or hydroxyethyl tether (6n) were endowed with improved anti-HIV activity compared to HI-236. NNRTI activity was confirmed by a cell-free RT assay on six of the derivatives in which 6c returned an IC(50) of 3.8 nM compared to 28 nM for HI-236, establishing it as an improved lead for HI-236. The structure-activity profile is discussed in terms of potential interactions in the NNRTI pocket as suggested by a docking model using AutoDock, which have a bearing on the bifunctional drug design.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013890 Thiourea A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
February 2019, ACS medicinal chemistry letters,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
February 2014, Bioorganic & medicinal chemistry,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
May 2012, European journal of medicinal chemistry,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
August 2012, ACS medicinal chemistry letters,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
September 2009, Bioorganic & medicinal chemistry letters,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
September 2006, Bioorganic & medicinal chemistry letters,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
May 2016, Expert opinion on therapeutic patents,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
June 2012, ACS medicinal chemistry letters,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
July 2010, Journal of medicinal chemistry,
Roger Hunter, and Yassir Younis, and Clare I Muhanji, and Tanith-Lea Curtin, and Kevin J Naidoo, and Melissa Petersen, and Christopher M Bailey, and Aravind Basavapathruni, and Karen S Anderson
June 2001, Journal of medicinal chemistry,
Copied contents to your clipboard!